Clinical trials: Polycystic Kidney, Autosomal Dominant
Polycystic Kidney, Autosomal Dominant
Bosutinib For Autosomal Dominant Polycystic Kidney Disease
This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kidney volume greater than or…
- Trial name
- NCT01233869
- Testing
- Bosutinib
- Where
- 67 sites in United States, Australia and 15 more
- Volunteers
- 172 people
- Sponsor
- Pfizer
Autosomal Dominant Polycystic Kidney Disease
A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
Recent evidence has shown that kidney volume predicts the likelihood of developing renal insufficiency over a finite length of time in ADPKD, suggesting a linkage between the growth of cysts and the harm they do to kidney…
- Trial name
- NCT01810614
- Testing
- ADPKD Diet
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Kansas
Autosomal Dominant Polycystic Kidney Disease
ADPKD Cohort Study
The purpose of this study is to find out if radiology tests of the kidneys as opposed to glomerular filtration (GFR) tests (GFR test - a lab test that measures kidney function) follow progression of polycystic kidney disease…
- Trial name
- NCT02084849
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Emory University
Polycystic Kidney Diseases
Everolimus on CKD Progression in ADPKD Patients
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.
- Trial name
- NCT01009957
- Testing
- Everolimus
- Where
- 7 sites in Italy
- Volunteers
- 71 people
- Sponsor
- A. Manzoni Hospital
Autosomal Dominant Polycystic Kidney Disease
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
EuroCYST initiative aims to build a large, well-characterized cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) subjects who are followed in a longitudinal observational cohort study has the potential to identify…
- Trial name
- NCT02187432
- Where
- 14 sites in Belgium, Czechia and 8 more
- Volunteers
- 1,100 people
- Sponsor
- Andreas L. Serra
Polycystic Kidney Diseases
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This study is a prospective, randomized, open-label, pilot clinical trial designed to compare the effects of an agent that has antiproliferative (1,2), antiangiogenesis (3),and tumor-progression blocking capabilities (4), namely…
- Trial name
- NCT00286156
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Autosomal Dominant Polycystic Kidney Disease
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as…
- Trial name
- NCT00414440
- Testing
- Everolimus
- Where
- 24 sites in Austria, France and 1 more
- Volunteers
- 431 people
- Sponsor
- Novartis Pharmaceuticals
Autosomal Dominant Polycystic Kidney Disease, Hypertension
Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
A randomized, open-label single-center study investigates the efficacy and safety of bilateral renal artery sympathetic denervation by catheter-based radiofrequency ablation on blood pressure and disease progression control in…
- Trial name
- RAFALE (NCT01932450)
- Testing
- renal sympathetic denervation, antihypertensive drugs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mei changlin
Autosomal Dominant Polycystic Kidney Disease, Glomerular Filtration Rate > 40 ml/Min
Effects of Somatostatin on ADPKD Heart
Autosomal dominant polycystic kidney disease (ADPKD) is associated with early onset hypertension and left ventricular (LV) hypertrophy.
- Trial name
- NCT02119013
- Testing
- Octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Autosomal Dominant Polycystic Kidney Disease
Effects of Somatostatin on Liver in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a variety of extrarenal manifestations of which polycystic liver disease is most common.
- Trial name
- NCT02119052
- Testing
- octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD…
- Trial name
- NCT02115659
- Testing
- Triptolide-Containing Formulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Changzheng Hospital
Autosomal Dominant Polycystic Kidney Disease
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic…
- Trial name
- NCT00920309
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yale University
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The aim of our study is to investigate whether Rapamune used at a low dose (2 mg/d) retards cyst growth and slows renal functional deterioration in patients with ADPKD.
- Trial name
- NCT00346918
- Testing
- Sirolimus, Standard
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Adult Polycystic Kidney Disease
Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease
In patients with polycystic kidney disease, pain may be resistant to drug therapy and may reduce quality of life. This study investigate the effect of renal denervation on this pain.
- Trial name
- NCT02062671
- Testing
- renal denervation
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Odense University Hospital
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common hereditary renal disease, responsible for 8% to 10% of the cases of end stage renal disease (ESRD) in Western countries.
- Trial name
- ALADIN (NCT00309283)
- Testing
- Long-acting somatostatin, Saline solution
- Where
- 5 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Liver Disease
Polycystic Liver Disease in Kidney Transplant
The purpose of this study is to see if one kind of immunosuppressive drug has better effects for the patient's polycystic liver disease than another type.
- Trial name
- NCT00934791
- Testing
- Tacrolimus, Sirolimus, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
The general aim of this study in adult patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and severe renal insufficiency is to assess the safety and the efficacy of sirolimus (SRL) in slowing renal function…
- Trial name
- SIRENA-II (NCT01223755)
- Testing
- Sirolimus, conventional therapy
- Where
- Italy
- Volunteers
- 41 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease
Octreotide in Severe Polycystic Liver Disease
This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection…
- Conditions
- Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases
- Trial name
- NCT00426153
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Polycystic Kidney, Autosomal Dominant
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
There are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with Autosomal dominant polycystic kidney disease (ADPKD), the association between serum uric acid level…
- Trial name
- NCT01589705
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- TC Erciyes University
ADPKD
The Vienna RAP Pilot Study
The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.
- Trial name
- RAP (NCT01632605)
- Testing
- Sirolimus
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna